<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04112498</url>
  </required_header>
  <id_info>
    <org_study_id>CA224-087</org_study_id>
    <nct_id>NCT04112498</nct_id>
  </id_info>
  <brief_title>A Phase 1, Bioavailability Study of Relatlimab in Combination With Nivolumab</brief_title>
  <official_title>A Phase 1, Multi-Tumor, Bioavailability Study of Relatlimab in Combination With Nivolumab</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will characterize the movement of drugs within the body, evaluate safety and&#xD;
      determine to which extent the body can process relatlimab in combination with nivolumab in&#xD;
      subjects with certain advanced tumors&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 1, 2019</start_date>
  <completion_date type="Anticipated">August 18, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 17, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>maximum observed serum concentration (Cmax)</measure>
    <time_frame>approximately 60 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>time of maximum observed serum concentration (Tmax)</measure>
    <time_frame>approximately 60 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>area under the time-concentration curve over the dosing interval AUC (TAU)</measure>
    <time_frame>approximately 60 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Observed concentration at the end of the dosing interval (Ctau)</measure>
    <time_frame>approximately 60 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Serious Adverse Events (SAEs)</measure>
    <time_frame>approximately 2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Adverse Events (AEs)</measure>
    <time_frame>approximately 2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Adverse Events leading to discontinuation</measure>
    <time_frame>approximately 2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of deaths</measure>
    <time_frame>approximately 2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of laboratory abnormalities</measure>
    <time_frame>approximately 2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverese Events (AEs) in the broad SMQ of Anaphylactic Reaction</measure>
    <time_frame>approximately 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of events within the hypersensitivity/infusion reaction select AE category</measure>
    <time_frame>approximately 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of anti-relatlimab antibodies and neutralizing antibodies (if applicable)</measure>
    <time_frame>approximately 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of anti-nivolumab antibodies and neutralizing antibodies (if applicable)</measure>
    <time_frame>approximately 2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>nivolumab + relatlimab + rHuPH20</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>relatlimab</intervention_name>
    <description>Specified dose on Specified days</description>
    <arm_group_label>nivolumab + relatlimab + rHuPH20</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nivolumab</intervention_name>
    <description>Specified dose on Specified days</description>
    <arm_group_label>nivolumab + relatlimab + rHuPH20</arm_group_label>
    <other_name>Opdivo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rHuPH20</intervention_name>
    <description>Specified dose on Specified days</description>
    <arm_group_label>nivolumab + relatlimab + rHuPH20</arm_group_label>
    <other_name>Enhanze</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding Bristol-Myers Squibb Clinical Trial participation, please&#xD;
        visit www.BMSStudyConnect.com&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologic or cytologic confirmation of (unresectable and/or metastatic) advanced&#xD;
             solid tumors&#xD;
&#xD;
          -  Melanoma&#xD;
&#xD;
          -  Metastatic squamous or non- squamous non-small cell lung cancer (NSCLC)&#xD;
&#xD;
          -  Gastric adenocarcinoma (includes gastro-esophageal junction)&#xD;
&#xD;
          -  Hepatocellular carcinoma (HCC)&#xD;
&#xD;
          -  Squamous cell carcinoma of the head and neck (SCCHN)&#xD;
&#xD;
          -  Renal cell carcinoma (RCC)&#xD;
&#xD;
          -  Bladder cancer&#xD;
&#xD;
          -  Participants must have received available standard therapies&#xD;
&#xD;
          -  Women and men must agree to follow instructions for method of contraception&#xD;
&#xD;
          -  Measureable disease as per RECIST version 1.1 criteria&#xD;
&#xD;
          -  Participants must have an Eastern Cooperative Oncology Group (ECOG) performance status&#xD;
             of 0 or 1&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participants must not have active brain metastases or leptomeningeal metastases&#xD;
&#xD;
          -  Participants with HCC must not have any history of hepatic encephalopathy, any prior&#xD;
             (within 1 year) or current clinically significant ascites&#xD;
&#xD;
          -  History of allergy or hypersensitivity to study drug components&#xD;
&#xD;
          -  Participants with serious or uncontrolled cardiovascular disease&#xD;
&#xD;
          -  Excluding patients with serious or uncontrolled medical disorders&#xD;
&#xD;
          -  Participants with a condition requiring systemic treatment with either corticosteroids&#xD;
             (&gt; 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14&#xD;
             days of start of study treatment&#xD;
&#xD;
          -  Participants with an active, known, or suspected autoimmune disease&#xD;
&#xD;
          -  Participants must not have evidence of organ dysfunction or any clinically significant&#xD;
             deviation from normal in physical examination, vital signs, ECG or clinical laboratory&#xD;
             determinations beyond what is consistent with the target population&#xD;
&#xD;
        Other protocol defined inclusion/exclusion Criteria could apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601-1914</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html</url>
    <description>BMS Clinical Trial Information</description>
  </link>
  <link>
    <url>https://www.bmsstudyconnect.com/s/US/English/USenHome</url>
    <description>BMS Clinical Trial Patient Recruiting</description>
  </link>
  <link>
    <url>https://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>October 1, 2019</study_first_submitted>
  <study_first_submitted_qc>October 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 2, 2019</study_first_posted>
  <last_update_submitted>September 13, 2021</last_update_submitted>
  <last_update_submitted_qc>September 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

